Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Obesity Treatments

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

The setback reinforces Lilly’s advantage — Novo now targets higher doses with an FDA decision expected late 2026.

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study